Search Results - "Levitt, Nicola"

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer by Abraham, Jean E., Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M., Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N., Worley, Joanna R., Chhabra, Anita, Qian, Wendi, Vallier, Anne-Laure, Hardy, Richard M., Chan, Steve, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P., Sutherland, Stephanie, Staples, Emma, Scott, Lucy C., Davies, Mark, Palmer, Cheryl A., Moody, Margaret, Churn, Mark J., Newby, Jacqueline C., Mukesh, Mukesh B., Chakrabarti, Amitabha, Roylance, Rebecca R., Schouten, Philip C., Levitt, Nicola C., McAdam, Karen, Armstrong, Anne C., Copson, Ellen R., McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena M.

“…PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1 , 2 , who were…”
Get full text

Caretaker tumour suppressor genes that defend genome integrity by Levitt, Nicola C, Hickson, Ian D

“…Cancers arise as a result of genetic changes that impact upon cell proliferation through promoting cell division and/or inhibiting cell death. Tumour…”
Get full text

Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles by Mehta, Shaveta, Hughes, Nicholas P., Buffa, Francesca M., Li, Sonia P., Adams, Rosemary F., Adwani, Asha, Taylor, N. Jane, Levitt, Nicola C., Padhani, Anwar R., Makris, Andreas, Harris, Adrian L.

“…Antiangiogenic therapy is a promising approach for the treatment of breast cancer. In practice, however, only a subset of patients who receive antiangiogenic…”
Get full text

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer by LEVITT, Nicola C, ESKENS, Ferry A. L. M, NAKAJIMA, Motowo, TALBOT, Denis C, STEWARD, William P, HARRIS, Adrian L, VERWEIJ, Jaap, O'BYRNE, Ken J, PROPPER, David J, DENIS, Louis J, OWEN, Samantha J, CHOI, Les, FOEKENS, John A, WILNER, Sue, WOOD, Jeanette M

“…This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and…”
Get full text

Potential Role for the BLM Helicase in Recombinational Repair via a Conserved Interaction with RAD51 by Wu, Leonard, Davies, Sally L., Levitt, Nicola C., Hickson, Ian D.

“…Bloom's syndrome (BS) is an autosomal recessive disorder that predisposes individuals to a wide range of cancers. The gene mutated in BS, BLM, encodes a member…”
Get full text

Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase IIα Expression by BRAYBROOKE, Jeremy P, LEVITT, Nicola C, JOEL, Simon, DAVIS, Theresa, MADHUSUDAN, Srinivasan, TURLEY, Helen, WILNER, Sue, HARRIS, Adrian L, TALBOT, Denis C

“…Purpose: There is substantial interpatient variability in etoposide pharmacokinetics. Pharmacokinetic adjustment to specific plasma concentrations may make it…”
Get full text

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer by Drewett, Lynsey, Lucey, Rebecca, Pinilla, Karen Andrea, Grybowicz, Louise, Wulff, Jerome, Dayimu, Alimu, Demiris, Nikos, Vallier, Anne-Laure, Qian, Wendi, Machin, Andrea, McAdam, Karen, Roylance, Rebecca, Copson, Ellen, Armstrong, Anne C., Levitt, Nicola, Provenzano, Elena, Tischkowitz, Marc D., McMurtry, Emma, Earl, Helena Margaret, Abraham, Jean

“…TPS619 Background: Triple negative breast cancers (TNBCs) are a biologically diverse and aggressive subgroup lacking targeted therapy. TNBC and germline BRCA…”
Get full text

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) by Turner, Nicholas, Saura, Cristina, Aftimos, Philippe, van den Tweel, Evelyn, Oesterholt, Mayke, Koper, Norbert, Colleoni, Marco, Kaczmarek, Emilie, Punie, Kevin, Song, Xinni, Armstrong, Anne, Bianchi, Giulia, Stradella, Agostina, Ladoire, Sylvain, Lim, Joline Si Jing, Quenel-Tueux, Nathalie, Tan, Tira J, Escrivá-de-Romaní, Santiago, O'Shaughnessy, Joyce

“…Human epidermal growth factor receptor 2 (HER2)-targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop…”
Get full text

Abstract OT2-24-01: PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients by Drewett, Lynsey M, Pinilla, Karen A, Grybowicz, Louise, Wulff, Jerome, Dayimu, Alimu, Demiris, Nikolaos, Martin, Jessica, de Pontes, Camila Maida, Johnson, Nicola, Harvey, Caron, Demir, Erdem, Green, Kimberley St John, Jones, James, Young, Gemma, Vallier, Anne-Laure, Qian, Wendi, Machin, Andrea, McAdam, Karen, Roylance, Rebecca, Copson, Ellen R, Armstrong, Anne, Levitt, Nicola, Provenzano, Elena, Tischkowitz, Marc, McMurtry, Emma, Earl, Helena, Abraham, Jean E

“…Abstract Background: Triple Negative Breast Cancers (TNBC) are a biologically diverse and aggressive subgroup lacking targeted therapy. Germline BRCA (gBRCA)…”
Get full text

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial by Coombes, R Charles, Tovey, Holly, Kilburn, Lucy, Mansi, Janine, Palmieri, Carlo, Bartlett, John, Hicks, Jonathan, Makris, Andreas, Evans, Abigail, Loibl, Sibylle, Denkert, Carsten, Murray, Elisabeth, Grieve, Robert, Coleman, Robert, Borley, Annabel, Schmidt, Marcus, Rautenberg, Beate, Kunze, Catarina Alisa, Rhein, Uwe, Mehta, Keyur, Mousa, Kelly, Dibble, Tessa, Lu, Xiao Lou, von Minckwitz, Gunter, Bliss, Judith M

“…Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast…”
Get more information

Abstract CT012: PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC) by Abraham, Jean E., Pinilla, Karen, Grybowicz, Louise, Dayimu, Alimu, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M., Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N., Worley, Joanna R., Chhabra, Anita, Qian, Wendi, Hardy, Richard M., Chan, Stephen, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P., Sutherland, Stephanie, Staples, Emma, Scott, Lucy C., Davies, Mark, Palmer, Cheryl A., Moody, Margaret, Churn, Mark J., Newby, Jacqueline C., Mukesh, Mukesh B., Chakrabarti, Amitabha, Roylance, Rebecca R., Schouten, Philip C., Levitt, Nicola, McAdam, Karen, Armstrong, Anne C., Copson, Ellen R., McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena

“…Abstract Background: TNBCs in patients (pts) who are germline BRCA wild type (gBRCAwt) may show homologous recombination deficiency and genomic instability,…”
Get full text

Abstract CT562: PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients by Drewett, Lynsey, Pinilla, Karen A., Grybowicz, Louise, Wulff, Jerome, Dayimu, Alimu, Demiris, Nikolaos, Lucey, Rebecca, Vallier, Anne-Laure, Qian, Wendi, Machin, Andrea, McAdam, Karen, Roylance, Rebecca, Copson, Ellen R., Armstrong, Anne, Levitt, Nicola, Provenzano, Elena, Tischkowitz, Marc, McMurtry, Emma, Earl, Helena, Abraham, Jean E.

“…Abstract Background: Triple Negative Breast Cancers (TNBC) are a biologically diverse and aggressive subgroup lacking targeted therapy. TNBC and Germline BRCA…”
Get full text

Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles by MEHTA, Shaveta, HUGHES, Nicholas P, HARRIS, Adrian L, BUFFA, Francesca M, LI, Sonia P, ADAMS, Rosemary F, ADWANI, Asha, JANE TAYLOR, N, LEVITT, Nicola C, PADHANI, Anwar R, MAKRIS, Andreas

Get full text

Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression by Braybrooke, Jeremy P, Levitt, Nicola C, Joel, Simon, Davis, Theresa, Madhusudan, Srinivasan, Turley, Helen, Wilner, Sue, Harris, Adrian L, Talbot, Denis C

“…There is substantial interpatient variability in etoposide pharmacokinetics. Pharmacokinetic adjustment to specific plasma concentrations may make it possible…”
Get full text

A pause site for RNA polymerase II is associated with termination of transcription by Enriquez‐Harris, P., Levitt, N., Briggs, D., Proudfoot, N.J.

“…Termination of transcription by RNA polymerase II has been postulated to involve a pausing process. We have identified such a pause signal, 350 bp into the 3′…”
Get full text